BioWorld MedTech

Oct. 21, 2011

Abbott reports plan to split into two separate companies

Two companies are better than one or so Abbott (Abbott Park, Illinois) has decided. The company plans to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Read More

Crimson's research memo details total cost of device documentation

International report: Cook's Spectrum Turbo-Ject PICC available in Canada

Washington roundup: FDA urged to tread lightly on artificial pancreas guidance

Agreements/contracts: Zimmer to distribute Benvenue's Kiva VCF

Deals roundup: Misonix sheds lab, forensic business for $1.5 million

Financings roundup: Sphere Medical looking to raise $24 million in an IPO

HIT roundup: Segasist wins first FDA 510(k) for Segasist P-AC

People in the News

Med-Tech Notes: RF Surgical works with UNC hospitals

Product Briefs

CareFusion initiates Class I recall of EnVe ventilators

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...